Human tnfrsf25 antibody
AssigneePelican Therapeutics, Inc.
InventorTaylor H. Schreiber
Life of this patent
Estimating the term…
Abstract
Antibodies and antigen binding fragments that bind specifically to TNFRSF25 are provided herein. Methods for using the antibodies and antigen binding fragments to, for example, stimulate proliferation of human T cells (e.g., CD8+ T cells) and to treat cancer patients also are provided.
Claims12
1-31. (canceled)
A human or humanized monoclonal antibody that specifically binds to TNFRSF25, wherein the antibody comprises:
- (a) a heavy chain comprising a CDR1 sequence as set forth in SEQ ID NO:4, a CDR2 sequence as set forth in SEQ ID NO:6, and a CDR3 sequence as set forth in SEQ ID NO:8;
- and
- (b) a light chain comprising a CDR1 sequence as set forth in SEQ ID NO:11, a CDR2 sequence as set forth in SEQ ID NO:13, and a CDR3 sequence as set forth in SEQ ID NO:15;
- or
- (c) a set of six CDRs that comprises no more than four total amino acid substitutions in the set of six CDRs having the amino acid sequences set forth in SEQ ID NOS:4, 6, 8, 11, 13, and 15.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a human or humanized monoclonal antibody that specifically binds to TNFRSF25, wherein the antibody comprises:
- (a) a heavy chain comprising a CDR1 sequence as set forth in SEQ ID NO:4, a CDR2 sequence as set forth in SEQ ID NO:6, and a CDR3 sequence as set forth in SEQ ID NO:8;
- and
- (b) a light chain comprising a CDR1 sequence as set forth in SEQ ID NO:11, a CDR2 sequence as set forth in SEQ ID NO:13, and a CDR3 sequence as set forth in SEQ ID NO:15;
- or
- (c) a set of six CDRs that comprises no more than four total amino acid substitutions in the set of six CDRs having the amino acid sequences set forth in SEQ ID NOS:4, 6, 8, 11, 13, and 15.
38-44. (canceled)
(canceled)
Dependencies are inferred from the claim text.